Carl P. Blobel

Has grant

Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

iRhom2, a New Target for Treatment of TNF-Alpha-Dependent Pathologies

Open Date: 2013-06-21

Close Date: 2014-12-20

Grant: Close

Matrix Metalloproteinases Gordon Conference

Open Date: 2005-06-01

Close Date: 2010-05-31

Grant: Close

Role of ADAMs 9 and 15 in Proliferative Retinopathy

Open Date: 2004-09-06

Close Date: 2010-08-31

Grant: Close

iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling

Open Date: 2002-02-01

Close Date: 2020-03-31

Grant: Close

METALLOPROTEASE DISINTEGRIN MDC9

Open Date: 1999-02-01

Close Date: 2004-01-31

Articles (4)

Tylosis with oesophageal cancer (TOC) is a rare familial disorder caused by cytoplasmic mutations in inactive rhomboid 2 (iRhom2 or iR2, encoded by Rhbdf2). iR2 and the related iRhom1 (or iR1, encoded by Rhbdf1) are key regulators of the membrane-anchored metalloprotease ADAM17, which is required for activating EGFR ligands and for releasing pro-inflammatory cytokines such as TNFα (or TNF). A cytoplasmic deletion in iR2, including the TOC site, leads to curly coat or bare skin (cub) in mice, whereas a knock-in TOC mutation (toc) causes less severe alopecia and wavy fur. The abnormal skin and hair phenotypes of iR2cub/cub and iR2toc/toc mice depend on amphiregulin (Areg) and Adam17, as loss of one allele of either gene rescues the fur phenotypes. Remarkably, we found that iR1−/− iR2cub/cub mice survived, despite a lack of mature ADAM17, whereas iR2cub/cub Adam17−/− mice died perinatally, suggesting that the iR2cub gain-of-function mutation requires the presence of ADAM17, but not its catalytic activity. The iR2toc mutation did not substantially reduce the levels of mature ADAM17, but instead affected its function in a substrate-selective manner. Our findings provide new insights into the role of the cytoplasmic domain of iR2 in vivo, with implications for the treatment of TOC patients.

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Collaborators (1)

Stefan Lichtenthaler

Technical University of Munich

GERMANY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.